ArticleJournal of molecular histology2025
Effect of sufentanil on the proliferation, apoptosis, and epithelial-mesenchymal transition of ovarian cancer cells by regulating the SMAD3/SNAIL signaling pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ZBTB7A promotes malignant phenotypes in ovarian cancer through transcriptional activation of CRLF1.Oncology reports · 2026Article
- Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study sufentanil's effect on the proliferation, apoptosis, and epithelial-mesenchymal transition (EMT) of ovarian cancer cells by modulating the SMAD3/SNAIL signaling pathway. Ovarian cancer A2780 cells were exposed to sufentanil at varying concentrations of 0 ng/mL, 20 ng/mL, 40 ng/mL, 60 ng/mL, 80 ng/mL, and 100 ng/mL. The proliferation of A2780 cells was assessed using the CCK-8 method; A2780 cells were randomly divided into three groups: CON group (normal culture), SUF group (60 ng/mL sufentanil intervention), and SUF + ACA group (60 ng/mL sufentanil and 100 ng/mL activin A intervention). After 48 h of culture, cell migration was evaluated by the scratch assay; Cell invasion was assessed using the Transwell chamber assay; Cell apoptosis was measured via flow cytometry; The growth status of the cells was observed under an optical microscope; The expression of N-cadherin, E-cadherin, SMAD3, TGF-β, and SNAIL proteins was detected by Western blot. When the concentration of sufentanil was ≥ 20 ng/mL, it dose-dependently inhibited the proliferation of ovarian cancer A2780 cells; In comparison to the CON group, the number of A2780 cells in the SUF group was significantly reduced, some cells detached, cell migration and invasion abilities, and the expression levels of N-cadherin, SMAD3, TGF-β, and SNAIL proteins decreased, while the apoptosis rate and E-cadherin protein expression levels increased (P < 0.05); In comparison to the SUF group, the growth status of A2780 cells in the SUF + ACA group was good, cell migration and invasion abilities, and the expression levels of N-cadherin, SMAD3, TGF-β, and SNAIL proteins increased, while the apoptosis rate and E-cadherin protein expression levels decreased (P < 0.05). Sufentanil may inhibit the proliferation and epithelial-mesenchymal transition of ovarian cancer cells and promote cell apoptosis by inhibiting the SMAD3/SNAIL signaling pathway.
Indexed as
Identifiers
40032693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.